Advertisement

Serum homocysteine levels are affected by renal function during a 3-year period of minodronate therapy in female osteoporotic patients

  • Tsuyoshi Ohishi
  • Tomotada Fujita
  • Daisuke Suzuki
  • Tatsuya Nishida
  • Mitsuru Asukai
  • Yukihiro Matsuyama
Original Article
  • 67 Downloads

Abstract

Serum homocysteine is a possible marker to indicate bone quality. However, it is not clear whether changes are seen in serum homocysteine levels with long-term bisphosphonate therapy. We aimed to investigate the factors affecting serum homocysteine levels during a 3-year period of monthly minodronate therapy in osteoporotic women, and to examine if the serum homocysteine levels could reflect some aspects of bone metabolism. The study included 43 patients (age 72.3 ± 7.0 years) undergoing treatment for osteoporosis for the first time (New group) and 35 patients (age 74.4 ± 8.2 years) who switched from alendronate or risedronate to minodronate (Switch group). Minodronate (50 mg/every 4 weeks) was administered for 36 months. Lumbar, femoral neck, and total hip bone mineral densities (BMD), and serum homocysteine levels were monitored at baseline and after 9, 18, 27, and 36 months of treatment. Lumbar BMD increased significantly in both groups (New group 11.4%, Switch group 6.2%). However, femoral neck and total hip BMDs increased only in the New group (femoral neck 3.6%, total hip 4.1%). Serum homocysteine levels increased significantly at 18 and 27 months in all subjects. Multiple linear regression analysis revealed that changes in homocysteine levels during 18, 27, and 36 months significantly correlated with changes in creatinine clearance during the same corresponding periods (18 months: B = − 0.472, p = 0.003; 27 months: B = − 0.375, p = 0.021; 36 months: B = − 0.445, p = 0.012). Thus, serum homocysteine levels possibly reflect renal function instead of bone metabolism during minodronate therapy.

Keywords

Bisphosphonate Bone mineral density Homocysteine Minodronate Osteoporosis 

Notes

Acknowledgements

The authors would like to thank Yoshiaki Ito, Yasuyuki Takabayashi, and Yasuhide Suzuki, who are laboratory technicians at Enshu Hospital, for their assistance with blood sample preparation.

Compliance with ethical standards

Conflict of interest

The authors report no conflicts of interest. The authors are responsible for the content and writing of the paper.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

References

  1. 1.
    Mashiba T, Mori S, Burr DB, Komatsubara S, Cao Y, Manabe T, Norimatsu H (2005) The effects of suppressed bone remodeling by bisphosphonates on microdamage accumulation and degree of mineralization in the cortical bone of dog rib. J Bone Miner Metab 23:36–42CrossRefPubMedGoogle Scholar
  2. 2.
    Saito M, Mori S, Mashiba T, Komatsubara S, Marumo K (2008) Collagen maturity, glycation induced-pentosidine, and mineralization are increased following 3-year treatment with incadronate in dogs. Osteoporos Int 19:1343–1354CrossRefPubMedGoogle Scholar
  3. 3.
    Bala Y, Depalle B, Farlay D, Douillard T, Meille S, Follet H, Chapurlat R, Chevalier J, Boivin G (2012) Bone micromechanical properties are compromised during long-term alendronate therapy independently of mineralization. J Bone Miner Res 27:825–834CrossRefPubMedGoogle Scholar
  4. 4.
    Saito M, Marumo K (2010) Collagen cross-links as a determinant of bone quality: a possible explanation for bone fragility in aging, osteoporosis, and diabetes mellitus. Osteoporos Int 21:195–214CrossRefPubMedGoogle Scholar
  5. 5.
    Ohishi T, Fujita T, Suzuki D, Nishida T, Yamamoto K, Okabayashi R, Ushirozako H, Banno T, Matsuyama Y (2017) Changes of bone mineral density and serum pentosidine during a 27-month follow-up of monthly minodronate in osteoporotic patients. Endocr Res 42:232–240PubMedGoogle Scholar
  6. 6.
    Nakano M, Kubota M, Owada S, Nagai R (2013) The pentosidine concentration in human blood specimens is affected by heating. Amino Acids 44:1451–1456CrossRefPubMedGoogle Scholar
  7. 7.
    Homocysteine Studies Collaboration (2002) Homocysteine and risk of ischemic heart disease and stroke; a meta-analysis. JAMA 288:2015–2022CrossRefGoogle Scholar
  8. 8.
    Blouin S, Thaler HW, Korninger C, Schmid R, Hofstaetter JG, Zoehrer R, Phipps R, Klaushofer K, Roschqer P, Paschalis EP (2009) Bone matrix quality and plasma homocysteine levels. Bone 44:959–964CrossRefPubMedGoogle Scholar
  9. 9.
    Vacek TP, Kalani A, Voor MJ, Tyagi SC, Tyagi N (2013) The role of homocysteine in bone remodeling. Clin Chem Lab Med 51:579–590CrossRefPubMedCentralPubMedGoogle Scholar
  10. 10.
    Enneman AW, Swart KMA, Zillikens MC, van Dijk SC, van Wijingaarden PJ, Brouwer-Brolsma EM, Dhonukshe-Rutten RAM, Hofman A, Rivadeneira F, van der Cammen TJM, Lips P, de Groot CPGM, Uitterlinden AG, van Meurs JBJ, van Scoor NM, van der Velde N (2014) The association between plasma homocysteine levels and bone quality and bone mineral density parameters in older persons. Bone 63:141–146CrossRefPubMedGoogle Scholar
  11. 11.
    McLean RR, Jacques PF, Selhub J, Tucker KL, Samelson EJ, Broe KE, Hannan MT, Cupples LA, Kiel DP (2004) Homocysteine as a predictive factor for hip fracture in older persons. N Engl J Med 350:2042–2049CrossRefPubMedGoogle Scholar
  12. 12.
    Shiraki M, Kuroda T, Shiraki Y, Tanaka S, Higuchi T, Saito M (2011) Urinary pentosidine and plasma homocysteine levels at baseline predict future fractures in osteoporosis patients under bisphosphonate treatment. J Bone Miner Metab 29:62–70CrossRefPubMedGoogle Scholar
  13. 13.
    Yang J, Hu X, Zhang Q, Cao H, Wang J, Liu B (2012) Homocysteine level and risk of fracture: a meta-analysis and systematic review. Bone 51:376–382CrossRefPubMedGoogle Scholar
  14. 14.
    Chatani Y (2005) Minodronic acid hydrate as a new therapeutic agent for osteoporosis. Clin Calcium 15:9–14 (article in Japanese) PubMedGoogle Scholar
  15. 15.
    Dunford JE, Thompson K, Coxon FP, Luckman SP, Hahn FM, Poulter CD, Ebetino FH, Rogers MJ (2001) Structure–activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonate. J Pharmacol Exp Ther 296:235–242PubMedGoogle Scholar
  16. 16.
    Hagino H, Shiraki M, Fukunaga M, Nakano T, Takaoka K, Ohashi Y, Nakamura T, Matsumoto T (2012) Three years of treatment with minodronate in patients with postmenopausal osteoporosis. J Bone Miner Metab 30:439–446CrossRefPubMedGoogle Scholar
  17. 17.
    Orimo H, Hayashi Y, Fukunaga M, Sone T, Fujiwara S, Shiraki M, Kushida K, Miyamoto S, Soen S, Nishimura J, Oh-hashi Y, Hosoi T, Gorai I, Tanaka H, Igai T, Kishimoto H (2001) Osteoporosis diagnostic criteria for primary osteoporosis: year 2000 revision. J Bone Miner Metab 19:331–337CrossRefPubMedGoogle Scholar
  18. 18.
    Araki A, Sako Y (1987) Determination of free and total homocysteine in human plasma by high-performance liquid chromatography with fluorescence detection. J Chromatogr 422:43–52CrossRefPubMedGoogle Scholar
  19. 19.
    Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 12:31–41CrossRefGoogle Scholar
  20. 20.
    Kimoto A, Tanaka M, Nozaki Mori M, Fukushima S, Mori H, Ahioya T, Nakamura T (2013) Intermittent minodronic acid treatment with sufficient bone resorption inhibition prevents reduction in bone mass and strength in ovariectomized rats with established osteopenia comparable with daily treatment. Bone 55:189–197CrossRefPubMedGoogle Scholar
  21. 21.
    Nagira K, Hagino H, Kameyama Y, Teshima R (2013) Effects of minodronate on cortical bone response to mechanical loading in rats. Bone 53:277–283CrossRefPubMedGoogle Scholar
  22. 22.
    Yamagami Y, Mashiba T, Iwata K, Tanaka M, Nozaki K, Yamamoto T (2013) Effects of minodronic acid and alendronate on bone remodeling, microdamage accumulation, degree of mineralization and bone mechanical properties in ovariectomized cynomolgus monkeys. Bone 54:1–7CrossRefPubMedGoogle Scholar
  23. 23.
    Jin A, Cobb J, HansenU Bhattacharya R, Reinhard C, Vo N, Atwood R, Li J, Karunaratne A, Wiles C, Abel R (2017) The effect of long-term bisphosphonate therapy on trabecular bone strength and microcrack density. Bone Joint Res 6:602–609.  https://doi.org/10.1302/2046-3758.610.BJR-2016-0321.R1 CrossRefPubMedCentralPubMedGoogle Scholar
  24. 24.
    Ma S, Goh EL, Jin A, Bhattacharya R, Boughton OR, Patel B, Karunaratne A, Vo NT, Atwood R, Cobb JP, HansenU Abel RL (2017) Long-term effects of bisphosphonate therapy: perforations, microcracks and mechanical properties. Sci Rep 7:43399.  https://doi.org/10.1038/srep43399 CrossRefPubMedCentralPubMedGoogle Scholar
  25. 25.
    Tariq S, Tariq S, Alam SS, Baig M (2015) Effect of ibandronate therapy on serum homocysteine and leptin in postmenopausal osteoporotic females. Osteoporos Int 26:1187–1192CrossRefPubMedGoogle Scholar
  26. 26.
    Arnadottir M, Hultberg B, Nisson-Ehle P, Thysell H (1996) The effect of reduced glomerular filtration rate on plasma total homocysteine concentration. Scand J Clin Lab Investig 56:41–46CrossRefGoogle Scholar
  27. 27.
    Francis ME, Eggers PW, Hostetter TH, Briggs JP (2004) Association between serum homocysteine and markers of impaired kidney function in adults in the United States. Kidney Int 66:303–312CrossRefPubMedGoogle Scholar
  28. 28.
    Gerdhem P, Ivaska KK, Isaksson A, Pettersson K, Väänänen HK, Obrant KJ, Åkesson K (2007) Associations between homocysteine, bone turnover, BMD, mortality, and fracture risk in elderly women. J Bone Miner Res 22:127–134CrossRefPubMedGoogle Scholar
  29. 29.
    Fujita Y, Iki M, Tamaki J, Kouda K, Yura A, Kadowaki E, Sato Y, Moon JS, Tomioka K, Okamoto N, Kurumatani N (2013) Renal function and bone mineral density in community-dwelling elderly Japanese men: the Fujiwara-kyo Osteoporosis Risk in Men (FORMEN) study. Bone 56:61–66CrossRefPubMedGoogle Scholar
  30. 30.
    LeBoff MS, Narweker R, LaCroix A, Wu L, Jackson R, Lee J, Bauer DC, Cauley J, Kooperberg C, Lewis C, Thomas AM, Cummings S (2009) Homocysteine levels and risk of hip fracture in postmenopausal women. J Clin Endocrinol Metab 94:1207–1213CrossRefPubMedCentralPubMedGoogle Scholar
  31. 31.
    Miller PD (2011) The kidney and bisphosphonates. Bone 49:77–81CrossRefPubMedGoogle Scholar
  32. 32.
    Yamada C, Fujimoto S, Ikeda K, Nomura Y, Matsubara A, Kanno M, Shide K, Tanaka K, Imai E, Fukuwatari T, Shibata K, Inagaki N (2011) Relationship of homocysteine and homocysteine-related vitamins to bone mineral density in Japanese patients with type 2 diabetes. J Diabetes Investig 2:233–239CrossRefPubMedGoogle Scholar

Copyright information

© The Japanese Society for Bone and Mineral Research and Springer Japan KK, part of Springer Nature 2018

Authors and Affiliations

  • Tsuyoshi Ohishi
    • 1
  • Tomotada Fujita
    • 1
  • Daisuke Suzuki
    • 1
  • Tatsuya Nishida
    • 1
  • Mitsuru Asukai
    • 1
  • Yukihiro Matsuyama
    • 2
  1. 1.Department of Orthopedic SurgeryEnshu HospitalHamamatsuJapan
  2. 2.Department of Orthopedic SurgeryHamamatsu University School of MedicineHamamatsuJapan

Personalised recommendations